Filtered By:
Cancer: Leukemia
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 113661 results found since Jan 2013.
Scurvy, abnormal MRI, and gelatinous bone marrow in an adolescent with avoidant restrictive food intake disorder
ConclusionsAlthough this patient had common manifestations of scurvy, including perifollicular petechial hemorrhagic rash, joint effusions, anemia, and recurrent fevers, she still underwent an extensive workup. Clinicians should be aware that scurvy can present with multiple symptoms that mimic infectious, rheumatic, oncologic and hematological disease. Clinicians should have a high index of suspicion for scurvy in patients with malnutrition and eating disorders.
Source: Journal of Eating Disorders - March 20, 2023 Category: Eating Disorders & Weight Management Source Type: research
Abstract IA14: Multilevel sources of bias as determinants of treatment disparities
Race disparities in cancer incidence and mortality continue to persist. Unequal treatment (IOM, 2003) for Blacks compared to Whites, is a key factor driving disparities in survivorship and mortality. Research documenting disparities in cancer treatment has shown, for example, that when compared to Whites, Black patients have less access and/or information about clinical trials, are more likely to be under dosed when receiving chemotherapy for breast cancer, are less likely to receive chemotherapy for leukemia, are given less information about hospice care, are less likely to receive adequate levels of pain medication, amon...
Source: Cancer Epidemiology Biomarkers and Prevention - April 14, 2016 Category: Cancer & Oncology Authors: Albrecht, T. L. Tags: Race, Admixture, and Ethnicity: Oral Presentations - Invited Abstracts Source Type: research
FDA Approves Gene Therapy Tested In Boston To Treat Adults With Lymphoma
TRENTON, N.J. (CBS/AP) — U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults.
The Food and Drug Administration allowed sales of the treatment from Kite Pharma. It uses the same technology, called CAR-T, as the first gene therapy approved in the U.S. in August, a treatment for childhood leukemia from Novartis Pharmaceuticals.
That Novartis treatment was tested in Boston. In those tests, Dana Farber and Brigham and Women’s Hospital cancer researchers found that 80 percent of lymphoma patients who underwent the treatment we...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 19, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Healthwatch Local News blood cancer Brigham and Women's Hospital Dana Farber FDA Gene Therapy Novartis Pharmaceuticals Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group
Conclusions:Our preliminary results of this observational epidemiologic study suggest that collection of clinical data of CML patients treated out of strictly clinical trials represent an essential tool for long/term treatment, able to observe setting strategies based on the clinical characteristics, the degree of response obtained, and the toxicity related to the therapy in overall CML population. We are planning to continue to analyze all these endpoints to estimate the response and toxicity according to ELN guidelines, and feasibility of treatment sequence in a cohort of patients treated in real-life.DisclosuresCastagne...
Source: Blood - November 21, 2018 Category: Hematology Authors: Specchia, G., Pregno, P., Nicolosi, M., Castagnetti, F., Martino, B., Breccia, M., Bonifacio, M., Stagno, F., Gozzini, A., Tiribelli, M., Bergamaschi, M., Pizzuti, M., Caocci, G., Luciano, L., Leoni, P., Guella, A., Falzetti, F., Di Lorenzo, R., Saccona, Tags: 632. Chronic Myeloid Leukemia: Therapy: Epidemiology, Prognosis, and Real Life Care Source Type: research
Development of arsenic trioxide sustained-release pellets for reducing toxicity and improving compliance.
Authors: Liu X, Zhou P, Yang Y, Liu J, Widjaya AS, Jiang Y
Abstract
Arsenic trioxide (ATO) is first-line drug for acute promyelocytic leukemia. Clinically, the continuously slow intravenous infusion is adopted to maintain effective blood concentration and reduce toxic effects, but it causes poor patient' compliance for a considerable infusion period. To overcome these disadvantages, we developed an oral ATO sustained-release preparation which were constructed via the ATO core pellets prepared by extrusion spheronization and followed by a coating membrane by fluid-bed technology. The prepared coated pellets displaye...
Source: Drug Development and Industrial Pharmacy - September 10, 2020 Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research
Introduction to Molecular Mechanisms in Notch Signal Transduction and Disease Pathogenesis.
Authors: Giaimo BD, Borggrefe T
Abstract
The Notch signaling pathway plays a pivotal role in development, physiology and diseases such as cancer. In this chapter, we first give an overview of the different molecular mechanisms that regulate Notch signaling. Each subject is covered in more depth in the subsequent chapters of this book. Next, we will use the inflammatory system as an example to discuss the physiological function of Notch signaling. This is followed by a discussion of recent advances in the different pathophysiological roles of Notch signaling in leukemia as well as a wide range of solid cancers. Fina...
Source: Advances in Experimental Medicine and Biology - July 22, 2018 Category: Research Tags: Adv Exp Med Biol Source Type: research
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Chronic myeloid leukemia (CML) is driven by the fusion kinase Bcr-Abl. Bcr-Abl tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), revolutionized CML therapy. Nevertheless, about 20 % of CMLs di...
Source: Cell Communication and Signaling - February 24, 2016 Category: Molecular Biology Authors: Sebastian Halbach, Zehan Hu, Christine Gretzmeier, Julia Ellermann, Franziska U. Wöhrle, Jörn Dengjel and Tilman Brummer Source Type: research
Multiple Myeloma and the Bone Marrow Niche
Multiple Myeloma (MM) is a disease of plasma cells with specific localization in the bone marrow. Recent studies have shown that MM is consistently preceded by MGUS. This has given rise to the concept of a myeloma precursor disease and raised questions about the biologic events leading to progression of these precursor states to symptomatic MM. The genomic complexity in MM was recently corroborated next generation sequencing that provided resolution pictures of the genetic changes in cancer cells and heterogeneity in tumors where tumor progression proceeds in a branching rather than in a linear manner, leading to substanti...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2015 Category: Hematology Authors: I.M. Ghobrial Source Type: research
Immunomodulatory Metabolites Released by the Frog-Killing Fungus Batrachochytrium dendrobatidis Fungal and Parasitic Infections
Batrachochytrium dendrobatidis is a fungal pathogen in the phylum Chytridiomycota that causes the skin disease chytridiomycosis. Chytridiomycosis is considered an emerging infectious disease linked to worldwide amphibian declines and extinctions. Although amphibians have well-developed immune defenses, clearance of this pathogen from the skin is often impaired. Previously, we showed that the adaptive immune system is involved in the control of the pathogen, but B. dendrobatidis releases factors that inhibit in vitro and in vivo lymphocyte responses and induce lymphocyte apoptosis. Little is known about the nature of the in...
Source: Infection and Immunity - November 10, 2015 Category: Infectious Diseases Authors: Rollins-Smith, L. A., Fites, J. S., Reinert, L. K., Shiakolas, A. R., Umile, T. P., Minbiole, K. P. C. Tags: Fungal and Parasitic Infections Source Type: research
T ‐Cell Acute Lymphoblastic Leukemia in Infants Has Distinct Genetic and Epigenetic Features Compared to Childhood Cases
This article is protected by copyright. All rights reserved.
Source: Genes, Chromosomes and Cancer - September 27, 2016 Category: Cancer & Oncology Authors: Mareike Doerrenberg, Andreas Kloetgen, Kebria Hezaveh, Wilhelm W össmann, Kirsten Bleckmann, Martin Stanulla, Martin Schrappe, Alice C McHardy, Arndt Borkhardt, Jessica I Hoell Tags: Research Article Source Type: research
Targeting BCL2 with BH3 mimetics: Basic Science and Clinical Application of Venetoclax in CLL and related B cell malignancies.
This article is protected by copyright. All rights reserved.
PMID: 27806433 [PubMed - as supplied by publisher]
Source: Clinical Pharmacology and Therapeutics - November 1, 2016 Category: Drugs & Pharmacology Authors: Roberts AW, Huang DC Tags: Clin Pharmacol Ther Source Type: research
Homozygous transcription factor 3 gene (TCF3) mutation is associated with severe hypogammaglobulinemia and B-cell acute lymphoblastic leukemia
Agammaglobulinemia is a rare primary immunodeficiency characterized by early-onset infections, absent peripheral B cells, and severe hypogammaglobulinemia. About 80% to 85% of patients have mutations in the Bruton tyrosine kinase gene causing X-linked agammaglobulinemia. Approximately half of the remaining patients are assigned to autosomal recessive agammaglobulinemia and have mutations in genes encoding for the pre –B-cell receptor or its downstream signaling proteins.1 Recently, a recurrent heterozygous dominant negative de novo mutation in the transcription factor 3 gene (TCF3; OMIM*147141) was identified in 4 unrela...
Source: Journal of Allergy and Clinical Immunology - May 19, 2017 Category: Allergy & Immunology Authors: Meriem Ben-Ali, Jing Yang, Koon Wing Chan, Imen Ben-Mustapha, Najla Mekki, Chaouki Benabdesselem, Fethi Mellouli, Mohamed Bejaoui, Wanling Yang, Lamia Aissaoui, Yu Lung Lau, Mohamed-Ridha Barbouche Tags: Letter to the Editor Source Type: research
Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study
ConclusionThe disease burden of CML decreased globally, especially in higher SDI countries in the past 28 years. The increasing incidence cases and death cases were mainly observed in lower SDI countries. Additionally, strategies to control modifiable risk factors such as smoking and high body mass index might be useful in diminishing mortality and DALYs.
Source: Experimental Hematology and Oncology - November 3, 2020 Category: Cancer & Oncology Source Type: research
The association between methylenetetrahydrofolate reductase C677 > T polymorphisms and risk of pediatric acute lymphoblastic leukemia in Asia
Conclusion: The results indicated that Asian children with TT genotype of MTHFR gene may have less risk of developing ALL.
Source: Journal of Cancer Research and Therapeutics - November 29, 2014 Category: Cancer & Oncology Authors: Shiguang LinQin LiuXiaoming Zeng Source Type: research
